PapersPMID:19809023
Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial.
What moved
1 findingHow to read these marks →- Decreases late-onset sepsis incidence (neonatal)
very limitedreplicated ×2
“Incidence of late-onset sepsis was significantly lower in the BLF and BLF plus LGG groups (9/153 [5.9%] and 7/151 [4.6%], respectively) than in the control group receiving placebo (29/168 [17.3%]) (risk ratio, 0.34; 95% confidence interval, 0.17-0.70; P = .002 for BLF vs control and risk ratio, 0.27; 95% confidence interval, 0.12-0.60; P < .001 for BLF plus LGG vs control).”
- Study
- RCT
- Effect
- 0.34 risk ratio, 95% CI 0.17 to 0.7
- Dose studied
- 100 mg/day orally from birth until day 30 of life (day 45 for neonates <1000 g at birth)
- Population
- Very low birth weight (<1500 g) neonates in 11 Italian tertiary neonatal intensive care units
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- VLBW (<1500 g) infants in 11 Italian tertiary neonatal intensive care units; oral bovine lactoferrin alone, bovine lactoferrin plus Lactobacillus rhamnosus GG, or placebo from birth until day 30 of life (day 45 for <1000 g); abstract only
- Participants
- 472
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 3